There is no reliable laboratory indicator of the onset of chronic graft-versus-host disease (cGVHD). This study looks at whether the expression of OX40, a member of the tumor necrosis factor receptor family, is related to the development of cGVHD in patients who underwent allogeneic hematopoietic stem cell transplantation. Peripheral blood mononuclear cells from 22 patients after day 100 were subjected to multicolor flow cytometry. The percentages of both OX40+CD4+ and OX40+CD8+T cells were significantly higher in patients with cGVHD than those without (P < .0001 and P = .001, respectively). Serial analyses showed that OX40+CD4+ T cells elevated before the onset of cGVHD and closely correlated with the therapeutic response. The expression of CD25, CD69, and HLA-DR was partially detectable on OX40+ T cells. These results indicate that serial measurement of OX40+ T cells is useful for predicting the onset as well as the therapeutic response of cGVHD and raise a possibility that the OX40/gp34 system is involved in the pathogenesis of cGVHD.

The increase in allogeneic hematopoietic stem cell transplantations (allo-HSCTs), particularly those using peripheral blood stem cells and involving donors other than HLA-identical siblings, has made the management of graft-versus-host disease (GVHD) a continuing problem. Although there have been advances in the prevention of acute (a) GVHD with the introduction of tacrolimus (FK506) and T-cell depletion, the incidence of chronic (c) GVHD has not decreased1 and the absence of reliable markers for predicting and monitoring cGVHD makes its control difficult.

The clinical manifestations of aGVHD and cGVHD are somewhat different. aGVHD is characterized by a triad of dermatitis, gastroenteritis, and hepatitis, whereas cGVHD is a more diverse syndrome, usually presenting with multiorgan involvement and closely related to autoimmune disease. Unlike aGVHD, T cells, which newly differentiate from donor hematopoietic stem cells, are thought to play more important roles in the development of cGVHD.2 

OX40, a member of the tumor necrosis factor receptor family, is expressed on activated T cells. The interaction of OX40 with its ligand, gp34, is shown to enhance T-cell proliferation.3In murine models, several reports showed that the OX40/gp34 system is involved in the process of GVHD4-7 as well as several autoimmune disease.8-10 In addition, studies with OX40- or gp34-deficient mice revealed that this system has a critical costimulatory function in dendritic cell/CD4+ T-cell interactions.11 

In this study, we measured the expression of OX40 on T cells after allo-HSCT to determine its correlation with the manifestations of cGVHD.

Twenty-two patients with hematologic malignancies and severe aplastic anemia undergoing bone marrow transplantation between 1998 and 2000 were included in this study. All patients were conditioned with myeloablative regimens. No patients received T-cell–depleted bone marrow or prophylactic anti-thymocyte globulin. Ten donors were related and 12 donors were unrelated, and HLA types were serologically 5- or 6-antigen matched between all pairs of patients and donors. Other characteristics of patients with cGVHD are shown in Table1. Peripheral blood mononuclear cells obtained more than 100 days after transplantation were subjected to 3-color flow cytometry by using FACScan (Becton Dickinson, San Jose, CA).

Cells were stained with fluorescein isothiocyanate–conjugated monoclonal antibodies (mAbs) against CD4, CD8, CD25, CD69, or HLA-DR (Becton Dickinson), peridinin chlorophyll protein–conjugated mAb recognizing CD3 (Becton Dickinson), and biotinylated 31512(anti-human OX40) in combination with phycoerythrin-conjugated streptavidin (Becton Dickinson). After gating T cells according to CD3 positivity, the ratio of OX40+ cells in CD4+ or CD8+ cells were calculated, and the relations of OX40+ cells with CD25+ cells, CD69+cells, and HLA-DR+ cells were determined. All data were analyzed with STATCEL program (Hisae Yanai). Two-group comparison was done on the analysis of variance and Student t test. Differences with P < .05 were considered to be statistically significant.

Of 22 patients enrolled, 11 patients (UPN 1-11) developed cGVHD and 6 of them were successfully treated with conventional immunosuppressive therapy such as prednisone. Among the remaining 5 patients, one patient (UPN 1) died of progressive cGVHD. Although the absolute numbers of CD4+ and CD8+ T cells varied considerably in each assay (data not shown), the percentages of both OX40+CD4+ T cells and OX40+CD8+ T cells in patients with cGVHD just before the introduction of immunosuppressive therapy were significantly higher than the peak value of OX40+ cells in patients without cGVHD (47.5% ± 17.9% versus 14.8% ± 11.6%,P < .0001; 35.3% ± 25.0% versus 5.8% ± 4.2%,P = .001; Figure 1A). The mean interval between the analysis and stem cell transplantation (SCT) is 233 days for patients with cGVHD and 274 days for those without cGVHD. Neither the severity of cGVHD (extensive type or limited type) nor the organ involved was correlated with the percentages of OX40+ cells (data not shown). CD25, CD69, and HLA-DR, which are expressed on activated T cells, were hardly or partially expressed on OX40+CD3+ T cells (Figure 1B). Neither the interval after transplantation, presence of aGVHD, nor immunosuppressive drugs for GVHD prophylaxis affected the expression of OX40 statistically (data not shown).

Fig. 1.

OX40 expression with cGVHD.

(A) Comparison of OX40 expression between patients with cGVHD (n = 11; closed circles and triangles) and without GVHD (n = 11; open circles and triangles). The mean interval between the analysis and SCT is 233 days for patients with cGVHD and 274 days for those without cGVHD. Each bar indicates the mean ± SD in each patient group. (B) Surface phenotype of T cells of a representative case with cGVHD. CD3+ T cells were gated and analyzed for expression of OX40, CD25, CD69, and HLA-DR. (C) Serial changes in the percentage of OX40+CD4+ T cells at 4 different time points around the onset of cGVHD. The first point is the day when patients visited the outpatient clinic 2 months before the onset of GVHD. The second point is the latest visit about 1 month before the onset. The third point is the time point at the onset of cGVHD just before immunosuppressive therapy. The fourth point is the next visit 1 to 2 weeks after the immunosuppressive therapy. The changes between the first 2 points and the comparison between the nonresponders (n = 5; closed point) and the responders (n = 5; open point) at the onset are depicted separately.

Fig. 1.

OX40 expression with cGVHD.

(A) Comparison of OX40 expression between patients with cGVHD (n = 11; closed circles and triangles) and without GVHD (n = 11; open circles and triangles). The mean interval between the analysis and SCT is 233 days for patients with cGVHD and 274 days for those without cGVHD. Each bar indicates the mean ± SD in each patient group. (B) Surface phenotype of T cells of a representative case with cGVHD. CD3+ T cells were gated and analyzed for expression of OX40, CD25, CD69, and HLA-DR. (C) Serial changes in the percentage of OX40+CD4+ T cells at 4 different time points around the onset of cGVHD. The first point is the day when patients visited the outpatient clinic 2 months before the onset of GVHD. The second point is the latest visit about 1 month before the onset. The third point is the time point at the onset of cGVHD just before immunosuppressive therapy. The fourth point is the next visit 1 to 2 weeks after the immunosuppressive therapy. The changes between the first 2 points and the comparison between the nonresponders (n = 5; closed point) and the responders (n = 5; open point) at the onset are depicted separately.

Close modal

In the 11 patients who developed cGVHD, we could serially follow the expression kinetics of OX40+ T cells before and after the onset of cGVHD and introduction of immunosuppressive therapy (Figure 1C). OX40+CD4+ T cells gradually increased before the appearance of clinical manifestations of cGVHD. In addition, the percentages of OX40+ cells in CD4+ T cells were significantly higher 1 month before the onset than 2 months before (23.7% ± 6.9% versus 12.3% ± 3.9%,P = .0007; Figure 1C). The percentage of OX40+cells just before the immunosuppressive therapy was closely correlated with the therapeutic response. These patients who did not respond to first line therapy for cGVHD tended to show a more highly elevated value than responders (nonresponders versus responders, 59.8% ± 17.9% versus 36.9% ± 10.2%, P = 0.037; Figure 1C). When the percentage of OX40+CD4+ T cells was elevated above 50%, the conventional immunosuppressive therapy was not effective, and more intensive salvage regimens for cGVHD, such as mycophenolate mofetil, were required. In contrast to OX40+CD4+ T cells, the percentage of OX40+CD8+ T cells did not correlate with the clinical response, although it elevated coincidentally with the onset of cGVHD (data not shown).

Our findings that the expression of CD25, CD69, and HLA-DR were hardly or partially expressed on OX40+CD3+ T cells implies that OX40+CD4+ T cells in patients with cGVHD might be distinct from recently activated T cells. Furthermore, we detected OX40+CD8+ T cells in almost all cGVHD patients. In mice ex vivo OX40 staining on tumor infiltrating CD8+ T cells was described.16 As far as we know, the present study first established that the expression of OX40 is inducible on human CD8+ T cells. The relationship between this subset and the effector cells of cGVHD is to be determined.

Our study for the first time showed a strong correlation between the expression of OX40 on T cells and cGVHD. In contrast, previous studies showed that monitoring OX40+ T cells was not useful for the prediction of aGVHD.17 We assume that the pathogenesis of aGVHD and cGVHD may not be identical2 and infections that are more common within 100 days after allo-HSCT18 might modify the expression of OX40.

Because accumulating evidence has indicated that OX40+ T cells play crucial roles in the development of several autoimmune diseases,9,10,13-15 the immune cell activation by the OX40/gp34 system might underlie more closely the pathogenesis of cGVHD. Considering that administration of anti-CD134L mAb significantly ameliorated aGVHD in mice,6 the selective blockade of OX40/gp34 system might be effective for GVHD in humans.

In conclusion, expression of OX40 in peripheral blood T cells can be used as a sensitive indicator of cGVHD after allo-HSCT and might be important for which chemotherapeutic drugs could be used. Modification of the OX40/gp34 system may enable us to better control cGVHD.

We thank Dr M. Sasada, Dr T. Okazaki, Dr A. Takahashi, Dr K. Imada, Dr N. Kadowaki, and Dr C. Ueda for their cooperation in collecting the blood samples, and we thank Ms. K. Fukunaga for expert technical assistance.

Supported by grants-in-aid from the Ministry of Education, Science, Sports and Culture of Japan.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Gaziev
D
Galimberti
M
Lucarelli
J
Polchi
P
Chronic graft-versus-host disease: is there an alternative to the conventional treatment?
Bone Marrow Transplant.
25
2000
689
696
2
Ferrara
JLM
Deeg
HJ
Graft-versus-host disease.
N Engl J Med.
324
1991
667
674
3
Kunitomi
A
Hori
T
Imura
A
Uchiyama
T
Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system.
J Leukoc Biol.
68
2000
111
118
4
Tittle
TV
Weinberg
AD
Steinkeler
CN
Mazziarz
RT
Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease.
Blood.
89
1997
4652
4658
5
Durie
F
Fanslow
WC
Zappone
J
et al
Conversion of chronic graft-versus-host disease to that of acute phenotype using in vivo administration of an antibody to OX40 (abstract).
FASEB J.
10
1996
1435
6
Tsukada
N
Akiba
H
Kobata
T
Aizawa
Y
Yagita
H
Okumura
K
Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation.
Blood.
95
2000
2434
2439
7
Stuber
E
Von Freier
A
Marinescu
D
Folsch
UR
Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease.
Gastroenterology.
115
1998
1205
1215
8
Weinberg
AD
Wallin
JJ
Jones
RE
et al
Target organ specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with EAE.
J Immunol.
152
1994
4712
4721
9
Weinberg
AD
Bourdette
DN
Sullivan
TJ
et al
Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis.
Nat Med.
2
1996
183
189
10
Higgins
LM
MacDonald
SA
Whittle
N
Crockett
N
Shields
JG
MacDonald
TT
Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein.
J Immunol.
162
1999
486
493
11
Murata
K
Ishii
N
Takano
H
et al
Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand.
J Exp Med.
191
2000
365
374
12
Imura
A
Hori
T
Imada
K
et al
The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells.
J Exp Med.
183
1996
2185
2195
13
Stuber
E
Bushenfeld
A
Luttges
J
von Freier
A
Arendt
T
Folsch
UR
The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis).
Eur J Clin Invest.
30
2000
594
599
14
Aten
J
Roos
J
Classen
N
et al
Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis.
J Am Soc Nephrol.
11
2000
1426
1438
15
Yoshioka
T
Nakajima
A
Akiba
H
et al
Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
Eur J Immunol.
30
2000
2815
2823
16
Kjaergaard
J
Tanaka
J
Kim
JA
Rothchild
K
Weinberg
A
Shu
S
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
Cancer Res.
60
2000
5514
5521
17
Gadisseur
APA
Gratama
JW
Lamers
C
van Esser
JWJ
Bolhuis
RLA
Cornelissen
JJ
Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
Bone Marrow Transplant.
23
1999
1013
1017
18
Deeg
HJ
Klingemann
HG
Phillips
GL
Van Zant
G
A Guide to Blood and Marrow Transplantation.
1999
Springer-Verlag
Berlin, Germany

Author notes

Toshiyuki Hori, Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan; e-mail thori@kuhp.kyoto-u.ac.jp.

Sign in via your Institution